The PMCPA has dug into the industry’s LinkedIn activities once again. | The PMCPA has dug into the industry’s LinkedIn ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Biotech company Immunai, which developed an AI-based immune system mapping technology for drug development, announces the ...

The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...

March 24 (UPI) --China reassured executives from American and European firms, including Apple, Qualcomm, Mastercard, Pfizer and AstraZeneca, that the world's second-largest economy is open for ...

Beijing assures US and other foreign business leaders that it will continue to open its market to investments and ...

Correspondence seen by The Irish Times shows several big pharma companies, such as Pfizer, MSD, Novo Nordisk and AstraZeneca, ...

AstraZeneca investing $2.5 billion in China ... 2025 Arvinas shares tumble as breast cancer drug with Pfizer shows mixed results Pfizer and Arvinas' experimental treatment failed to delay ...